Literature DB >> 2443206

Potential impact of immunobiotechnology on cancer therapy.

P J Guillou1.   

Abstract

Genetic engineering techniques allow large scale production of substances generated during the immune response and these may have therapeutic value by modifying the biological response to cancer.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2443206     DOI： 10.1002/bjs.1800740820

Source DB:  PubMed          Journal:  Br J Surg        ISSN： 0007-1323            Impact factor:   6.939


  3 in total

1.  Factors influencing the response and survival of patients with liver metastases from breast cancer receiving OK-432-combined adoptive immunotherapy.

Authors:  S Yamasaki; T Okino; N Kan; K Satoh; K Mise; Y Teramura; T Harada; H Kodama; T Hori; K Ohgaki
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.

Authors:  B Brooks; R C Rees
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

3.  Cytokines regulate the ability of human LAK-cells to kill human tumour cells in vitro.

Authors:  G Gallagher; F al-Azzawi; J Davis; W H Stimson
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.